PDK1 and neoplasm: In this study we not only reveal the tumor suppressive role of SPOP by targeting PDK1 for degradation and AKT inactivation, but also highlight combating PDK1-AKT pathway as a potent strategy to treat SPOP mutant-driven prostate cancer (Fig. 7).